Alnylam Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $593,166 | $500,919 | $659,825 | $494,333 |
Gross Profit | 490,349 | 415,014 | 591,153 | 428,357 |
EBITDA | -154,987 | -60,305 | 37,094 | -14,817 |
EBIT | -134,441 | -74,287 | 22,091 | -28,334 |
Net Income | -83,763 | -111,570 | -16,889 | -65,935 |
Net Change In Cash | 593,166 | 500,919 | 659,825 | 494,333 |
Free Cash Flow | -103,756 | 39,515 | 116,140 | -94,488 |
Cash | 966,428 | 1,099,920 | 968,492 | 681,879 |
Basic Shares | 128,590 | 128,590 | 126,733 | 126,138 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $2,248,243 | $1,828,292 | $1,037,418 | $844,287 |
Gross Profit | 1,924,873 | 1,517,886 | 868,601 | 704,143 |
EBITDA | -178,847 | -258,242 | -926,557 | -661,556 |
EBIT | -235,517 | -312,296 | -971,025 | -709,123 |
Net Income | -278,157 | -440,242 | -1,131,156 | -852,824 |
Net Change In Cash | 2,248,243 | 1,828,292 | 1,037,418 | 844,287 |
Cost of Revenue | 53,833 | 332,125 | ||
Free Cash Flow | -42,589 | 41,945 | -613,333 | -718,065 |
Cash | 127,133 | 812,688 | 866,394 | 819,975 |
Basic Shares | 128,590 | 124,906 | 121,689 | 118,451 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | $0.06 |
2024-09-30 | -$0.87 |
2024-06-30 | -$0.13 |
2024-03-31 | -$0.52 |
